Operating through 43 company-operated treatment centers, Greenbrook TMS Inc. is a leading provider of Transcranial Magnetic Stimulation (TMS), an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder (MDD), in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 160,000 TMS treatments to over 4,500 patients struggling with depression.
October 3, 2018 – Toronto, ON –
GREENBROOK TMS ANNOUNCES LISTING ON THE TORONTO STOCK EXCHANGE
September 27, 2018 – Toronto, ON –
GREENBROOK TMS ANNOUNCES FILING OF FINAL PROSPECTUS